Trijardy XR 2.5 mg/1

Trijardy XR 2.5 mg/1 is a combination medication containing empagliflozin, linagliptin, and metformin hydrochloride. It is designed to help manage type 2 diabetes by improving blood sugar control. This extended-release tablet is taken orally and is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.

Trijardy XR 2.5 mg/1 is primarily used to manage type 2 diabetes in adults. It works by combining three active ingredients to help lower blood sugar levels. Empagliflozin helps the kidneys remove excess glucose from the body, linagliptin improves insulin production, and metformin reduces glucose production in the liver. This medication is often prescribed as part of a comprehensive diabetes management plan, which may include diet and exercise.

Common effects of Trijardy XR 2.5 mg/1 may include symptoms such as nausea, diarrhea, and headache. Some users may also experience urinary tract infections or low blood sugar levels. These effects can vary from person to person and are not experienced by everyone who takes the medication. It is important to consult with a healthcare provider if any side effects are severe or persistent.

Trijardy XR 2.5 mg/1 should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should be stored at room temperature and kept out of reach of children. Patients with certain medical conditions, such as kidney or liver problems, should inform their healthcare provider before starting this medication.

Trijardy XR 2.5 mg/1 may interact with other medications, including certain antibiotics, antifungal agents, and other diabetes medications. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be limited while taking this medication, as it can increase the risk of low blood sugar levels.